Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease - PubMed
Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD) are two pathologies that share a bidirectional causal nexus, as CDI is known to have an aggravating effect on IBD and IBD is a known risk factor for CDI. The colonic involvement in IBD not only renders the host more …
Reappraisal of the clinical role of metronidazole therapy for Clostridioides difficile infection in Taiwan: A multicenter prospective study - PubMed
For Taiwanese adults with CDI, the failure rate of metronidazole therapy approached 50%, which suggests the reappraisal of the therapeutic role of metronidazole therapy, especially for patients with leukocytosis or underlying congestive heart failure.
Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.
Clostridioides difficile Poses a Challenge in Rural Areas, Patient Says - AJMC.com Managed Markets Network
Before she finally had successful treatment for her Clostridioides difficile infection in New Haven, Connecticut, Freda Pyles’ family physician in rural Pennsylvania was terrified and frustrated that he could not cure her and other patients.
Health care consequences of hospitalization with Clostrioides difficile infection: a propensity score matching study - BMC Infectious Diseases - BMC Infectious Diseases
Background Clostridiodies difficile infection (CDI) has been characterized by the Center for Disease Control and Prevention (CDC) as an urgent public health threat and a major concern in hospital, outpatient and extended-care facilities worldwide. Methods A retrospective cohort study of patients aged ≥ 18 hospitalized with CDI in New York State (NYS) between January 1, 2014–December 31, 2016. Data were extracted from NY Statewide Planning and Research Cooperative (SPARCS) and propensity score matching was performed to achieve comparability of the CDI (exposure) and non-CDI (non-exposure) groups. Of the 3,714,486 hospitalizations, 28,874 incidence CDI cases were successfully matched to 28,874 non-exposures. Results The matched pairs comparison demonstrated that CDI cases were more likely to be readmitted to the hospital at 30 (28.26% vs. 19.46%), 60 (37.65% vs. 26.02%), 90 (42.93% vs. 30.43) and 120 days (46.47% vs. 33.74), had greater mortality rates at 7 (3.68% vs. 2.0%) and 180 days (20.54% vs. 11.96%), with significant increases in length of stay and total hospital charges (p
Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System
Implementation of the CDI treatment pathway was associated with better clinical outcomes and hospital cost savings. The findings help validate real-world value of fidaxomicin for CDI disease management.
C. difficile infection: Current treatment options and challenges - BioPharma Dive
Clostridioides difficile infection is a highly contagious disease that affects 500,000 people in the U.S. and results in nearly 30,000 deaths per year.
C. Diff In 30 Minutes update covers new FDA antibiotic treatment and stool transfers - In 30 Minutes Guides
“Since I wrote the first edition of the book nearly a decade ago, a number of important discoveries have improved our management of C. diff,” Lamont said.
Gut microbiota and host inflammation states: personalized treatments for ulcerative colitis remission
Ulcerative colitis is a chronic debilitating inflammatory bowel disease with no curative treatment currently available. INRAE scientists have developed a novel predictive model of disease progression in pediatric patients that integrates both gut microbiota and host inflammation data.
Role of Real-Time Data in Healthcare - News-Medical.Net
AI and machine learning have been in use for the past decade and, since then, have acted as our primary modus for attaining trending data in health care facilities.
Validation of a health-related quality of life questionnaire in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a Phase 3 randomized trial
AbstractBackground. Debilitating symptoms of recurrent Clostridioides difficile infection (rCDI) often lead to long-term effects on health-related quality-of-li
Treatment and Outcomes of Clostridioides difficile Infection in Switzerland: A Two-Center Retrospective Cohort Study
Objectives: Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea, often complicated by severe infection and recurrence with increased morbidity and mortality. Data from large cohorts in Switzerland are scarce. We aimed to describe diagnostic a …
Validation of a health-related quality of life questionnaire in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a Phase 3 randomized trial - PubMed
Cdiff32 is a valid, reliable, and responsive disease-specific HRQOL questionnaire fit-for-purpose for interventional treatment trials. The significant improvement in non-recurrent patients by 8 weeks demonstrates the negative impact of rCDI on HRQOL.
High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Clostridioides Difficile Infection
Our study confirmed that the increase in the abundance of beneficial bacteria such as Bifidobacteriaceae, and Christensenellaceae were prominently evident during recovery after administration of a high dose of cholecalciferol. These findings indicate that vitamin D administration may b …
Battling Enteropathogenic Clostridia: Phage Therapy for Clostridioides difficile and Clostridium perfringens - PubMed
The pathogenic Clostridioides difficile and Clostridium perfringens are responsible for many health care-associated infections as well as systemic and enteric diseases. Therefore, they represent a major health threat to both humans and animals. Concerns regarding increasing antibiotic …